Buy-- Price 10.94 on Feb. 19 by Hilliard Lyons CZN's 9.1% dividend yield [makes it] one of the five highest-yielding stocks in the Standard & Poor's 500... . The stock has declined by 32% from its 52-week high ... yet fundamentals [haven't] materially changed. CZN typically has an [earnings before interest, depreciation, taxes and amortization] margin in the mid-50% range, [quite high among] rural local-exchange carriers... . We expect "08 [free cash flow] of $500 million. 13 target. Market-cap: $3.7 billion.

Buy-- Price 6.69 on Feb. 20 by Think Equity FBCM reported weak 4Q results [amid] a difficult capital-markets environment and subdued capital-raising ... Investment-banking revenue fell 62% y/o/y, a 54% sequential decrease. While ... FBCM's pipeline [looks] relatively solid, challenging market conditions could continue to weigh on capital-raising activity near-term. We're lowering FY08 EPS estimate from 76 cents to 11 cents but maintain Buy. Given net cash of $6 a share and book value of $7.91 a share, we believe downside ... is limited. Target: 8 [from 15]. Market-cap: $430 million.

Outperform-- Price 27.12 on Feb. 19 by Morgan Keegan [This leading international short-line railroad with 5,900+ track miles and another 3,700 via access arrangement] reported 4Q07 [earnings per share] of 37 cents -- beating our and management estimates... . Based on our increased fiscal-year "08 earnings estimate of $1.70 a share, GWR trades at 17.4 times... . GWR benefits from accretive acquisitions ... [plus] growth in nonfreight revenues and pricing power. Market-cap: $957 million.

Strong Buy-- Price 3.86 on Feb. 19 by Raymond James NovaMed reported normalized 4Q07 EPS from continuing operations of 8 cents... . Overall, 4Q results were better than expected (especially considering recent lack of enthusiasm for its shares -- trading at near-historic lows) and consistent with our recent upgrade on Jan. 25 from Outperform to Strong Buy (at $2.96), as same-facility revenue growth (+9% y/o/y) ... coupled with improved volumes in 4Q, [were seen to] act as catalysts for outperformance heading into 2008. Market-cap: $97 million.

Outperform-- Price 37.23 on Feb. 19 by Bear Stearns [Due to cost increases,] we are lowering our 1Q08 EPS to 27 cents (from 30 cents) and 2008 EPS to $3.22 (from $3.25). We maintain our "08 year-end target, 49, which we base on 13.5 times our 2009 EPS of $3.60. Risks relate to rising fuel expense and the impact of a slowing [of] leisure consumer[s] given continued macroeconomic weakness. Market-cap: $10.4 billion.

Neutral-- Price 23.80 on Feb. 19 by Jesup & Lamont We believe IT-contractor SINT is well-positioned with the Air Force and to benefit from transformation of the military. But ... given SINT's "07 organic growth of 3.2% down from 8% in 2006, we['d] stay on the sidelines... . For 2009E we forecast EPS $1.84. Market-cap: $316.5 million.

Buy-- Price 12 on Feb. 20 by Garp Research Despite a 60% jump in revenue and near doubling of EPS in 4Q07, TASR shares dropped by 10% ... in "07, TASR experienced a net decline in outstanding wrongful-death cases for the first time ever ... We think investor focus on gross margin compression is misplaced because the real story is the company's sizable operating leverage, which could lead to an incremental operating margin of 40% to 50% for "08. Market-cap: $725 million.

Hold-- Price 88 on Feb. 19 by Brean Murray Carret [Despite] concerns regarding results of oral treprostinil pivotal trials and launch of Viveta [for pulmonary arterial hypertension], we belie[ve] treprostinil is the best-in-class therapy for PAH and expect continued growth for the Remodulin franchise in "08, despite flat quarter/over/quarter. We now forecast 1Q08-4Q08 and year-end 2008 EPS to be: 49 cents, 39 cents, 48 cents, 33 cents, and $1.69, respectively. Market-cap: $1.8 billion.